How is Prostate Cancer that has spread to the liver treated

Treatment of Prostate Cancer That Has Spread to the Liver

Thank you for this important question. When prostate cancer spreads to the liver (or any organ outside the prostate and pelvis), it's called metastatic prostate cancer, and the treatment approach changes significantly from localized disease.

Understanding Your Situation

According to the NCCN Guidelines for Advanced-Stage Prostate Cancer, when prostate cancer has metastasized (spread) to organs like the liver, the cancer is treated as a systemic disease—meaning it requires whole-body therapy rather than local treatments like surgery or radiation to just one spot.

The Main Treatment Approach: Androgen Deprivation Therapy (ADT)

The foundation of treatment for metastatic prostate cancer is androgen deprivation therapy (ADT). Here's how it works:

What it does: ADT reduces testosterone (an androgen, or male hormone) in your body to very low levels—a point called "castration level." Since prostate cancer cells typically need testosterone to grow, lowering testosterone can slow or stop cancer growth.

How it's given:

• Hormone-blocking drugs (LHRH agonists or LHRH antagonists)
• Anti-androgen medications
• Sometimes surgical removal of the testicles (less common today)

Treatment Beyond ADT Alone: Combination Therapy

Important change in standard care: According to recent NCCN Guidelines and expert sources like Dr. [removed] Armstrong's research on advanced prostate cancer, ADT is no longer given alone. Treatment intensification is now standard, meaning your doctor will typically add one or two additional therapies to ADT. This is called:

• Doublet therapy (ADT + one additional drug)
• Triplet therapy (ADT + two additional drugs)

Additional Therapies That May Be Added

Depending on your specific situation, your oncologist may recommend:

1. Second Hormone Therapies (Androgen Receptor Blockers)

• Abiraterone (Zytiga)
• Enzalutamide (Xtandi)
• Apalutamide (ARN-509)
• Darolutamide (Nubeqa)

These drugs block the androgen receptor—essentially preventing testosterone from fueling cancer cells even when testosterone levels are low.

2. Chemotherapy

• Docetaxel (Taxotere) is commonly used with ADT for newly diagnosed metastatic disease
• This combination has been shown to help patients live longer

3. Targeted Therapies (If You Have Specific Mutations)

According to the NCCN Guidelines, if genetic testing shows you have mutations in DNA repair genes like BRCA1 or BRCA2, you may be eligible for:

• PARP inhibitors like olaparib (Lynparza) or talazoparib (Talzenna)
• These drugs prevent cancer cells from repairing damaged DNA, causing them to die

4. Radiopharmaceuticals (Radioactive Drugs)

• Lutetium-177 (Pluvicto): A targeted radioactive drug that finds prostate cancer cells throughout your body using a protein called PSMA. About one-third of patients have excellent responses.
• Radium-223 (Xofigo): Used specifically when cancer has spread to bones (though your liver involvement would need evaluation)

5. Immunotherapy

• Sipuleucel-T (Provenge): A vaccine-type therapy that boosts your immune system
• Pembrolizumab (Keytruda): An immune checkpoint inhibitor for patients with specific genetic markers (mismatch repair deficiency or high microsatellite instability)

Important Testing You Should Have

According to the guidelines and expert recommendations, before starting treatment, ask your doctor about:

1. Genetic/Molecular Testing - DNA and RNA sequencing of your tumor to identify actionable mutations (about 20% of patients have mutations that point to specific targeted drugs)
2. Liquid Biopsy - A blood test that can detect circulating tumor DNA to monitor your disease
3. PSMA-PET Scan - If considering radiopharmaceuticals like Pluvicto
4. Testosterone Level Testing - To confirm castration level during treatment

Questions to Ask Your Oncologist

Since YOUR specific situation requires your doctor's evaluation, here are key questions:

1. "Is my cancer hormone-sensitive or hormone-resistant?" (This determines which drugs are most appropriate)
2. "What genetic testing do you recommend, and what mutations should we look for?"
3. "Do you recommend doublet or triplet therapy for my case, and why?"
4. "Am I a candidate for radiopharmaceuticals like Pluvicto, and would a PSMA-PET scan help determine this?"
5. "What is your plan if my cancer becomes resistant to the first treatment?"
6. "Are there clinical trials I should consider?"

Key Points to Remember

• Metastatic prostate cancer with liver involvement is treated systemically (whole-body treatment)
• Treatment intensification with combination therapy is now standard of care
• Your specific treatment depends on whether your cancer is hormone-sensitive, your genetic mutations, and your overall health
• Multiple effective options exist, and your oncologist will sequence them based on your response
• Regular monitoring with PSA blood tests, imaging, and genetic testing helps track how well treatment is working

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.